OptimizeRx CorpOPRX

OptimizeRx Corp, the healthcare marketing technology outfit that sells an AI-guided platform called Micro-Neighborhood® Technology to pharmaceutical brands, reported quarterly revenue of $19.8 million for the three months ending 31 March 2026, a figure that sits 82% below the $109.4 million posted in the full-year 2025 10-K. The company’s balance sheet still looks tidy on paper-$167.3 million in assets against $37.7 million in liabilities-but the cash story is the one that matters, and here OptimizeRx burned $467,000 in operating cash during the quarter while booking a net loss of $495,000. Diluted earnings per share came in at -$0.03 on 18.8 million diluted shares, a figure that sharpens the optics when a billionaire trustee, Daniel Greco, quietly disclosed a 10.8% stake in a Schedule 13G filed with the SEC on 22 July 2026.

OptimizeRx markets itself as a precision healthcare marketing platform that connects clinically informed audience insights with omnichannel media activation to drive measurable outcomes like new prescriptions and impressions. The company’s product pages boast of “next best action” delivery using Micro-Neighborhood® Technology and a Dynamic Audience Activation Platform (DAAP) described as an AI-guided point-of-care content delivery system. The marketing promises scale-12,000 new prescriptions and $12.8 million in incremental revenue are quoted on the site-but the filings show a business that is still converting revenue at a modest clip and burning cash in operations. The platform’s imagery, complete with hero shots of dashboard interfaces, contrasts with the reality of a company that spent $3.4 million on R&D in the quarter and $21,000 on property, plant and equipment, while holding zero short-term investments and a cash pile of $20.2 million.

The company’s latest Schedule 13G reveals that Daniel Greco, through the Greco 2007 Trust U/A DTD 06/15/07, now holds 1,999,999 shares, representing 10.8% of the 18.5 million total shares outstanding. Greco also provided advisory services to the company for twelve months ending 15 June 2027, a fact disclosed in an 8-K filed on 12 June 2026. The optics are hard to ignore: a significant shareholder with a seat at the advisory table while the company’s diluted loss per share widens. The filings are clear; the marketing is aspirational.

OptimizeRx’s technology pages push a vision of precision targeting across the full pharma brand lifecycle, promising agencies “equip your agency with precision HCP and patient targeting” and publishers “deliver precise HCP and patient audiences for pharma advertisers.” The imagery underscores a claim to interoperability-delivering targeted content within existing health information technology systems-but the numbers don’t yet show the scale the visuals imply. The company’s cash conversion cycle remains negative in operating cash flow terms, and its R&D spend, while material at $3.4 million, has yet to translate into a clear inflection in net income or operating cash generation.

The company’s SEC filings can be browsed at the SEC’s EDGAR index for CIK 1448431, and the latest submissions can be parsed via the SEC submissions JSON feed. The company’s XBRL company facts provide additional machine-readable context on key metrics, but none of the filings yet show a revenue inflection that matches the ambition of the marketing copy. For now, the platform story outruns the balance sheet reality, leaving investors to weigh polished product pages against disclosed losses and negative operating cash flow.

If you want to see how OptimizeRx describes its Micro-Neighborhood® Technology, the company’s own product page offers the glossy version, complete with imagery and claims of activation-ready audiences. If you want the receipts, the SEC EDGAR filings-especially the 10-Q for 31 March 2026 and the recent 13G-are where the numbers live. The contrast is instructive: the promise of AI-driven care journeys versus the reality of -$0.03 diluted EPS and negative operating cash flow.